Clinical trial
Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
NCT00002952 · University of Chicago, Other · Completed
Key facts
| NCT number | NCT00002952 |
|---|---|
| Title | Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma |
| Official title | Phase I/II Study of Immunization With MAGE-3 Peptide-Pulsed Autologous PBMC Plus rhIL-12 in Patients With Metastatic Melanoma |
| Lead sponsor | University of Chicago, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | MART-1 antigen, recombinant MAGE-3.1 antigen, recombinant interleukin-12 |
| Enrollment | 20 |
| Start date | Jan 1, 1997 |
| Primary completion | Aug 1, 2002 |
| Completion | Nov 1, 2002 |
| First posted | Apr 22, 2004 |
| Last update posted | Sep 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: